Pier 88 Investment Partners LLC Has $845,000 Stock Position in Insulet Corporation $PODD

Pier 88 Investment Partners LLC lessened its stake in Insulet Corporation (NASDAQ:PODD) by 97.7% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,690 shares of the medical instruments supplier’s stock after selling 111,850 shares during the quarter. Pier 88 Investment Partners LLC’s holdings in Insulet were worth $845,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the stock. Campbell & CO Investment Adviser LLC acquired a new position in shares of Insulet during the second quarter worth approximately $1,081,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in Insulet in the 2nd quarter worth approximately $7,002,000. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in Insulet by 7.7% during the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 134,357 shares of the medical instruments supplier’s stock worth $42,212,000 after buying an additional 9,578 shares in the last quarter. Aviva PLC lifted its holdings in Insulet by 6.7% during the 2nd quarter. Aviva PLC now owns 52,189 shares of the medical instruments supplier’s stock worth $16,397,000 after buying an additional 3,282 shares in the last quarter. Finally, Los Angeles Capital Management LLC boosted its position in Insulet by 518.0% in the 2nd quarter. Los Angeles Capital Management LLC now owns 167,231 shares of the medical instruments supplier’s stock valued at $52,541,000 after buying an additional 140,169 shares during the last quarter.

Insider Buying and Selling at Insulet

In other news, SVP Prem Singh sold 687 shares of Insulet stock in a transaction on Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the transaction, the senior vice president directly owned 3,456 shares of the company’s stock, valued at $1,200,925.44. This trade represents a 16.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Laetitia Cousin sold 797 shares of the business’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the transaction, the senior vice president directly owned 3,890 shares of the company’s stock, valued at $1,356,870.90. This trade represents a 17.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.39% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on PODD. Leerink Partners boosted their target price on Insulet from $355.00 to $385.00 and gave the stock an “outperform” rating in a research report on Friday. BTIG Research reiterated a “buy” rating and issued a $370.00 price objective on shares of Insulet in a research report on Thursday. Rothschild & Co Redburn boosted their price objective on Insulet from $350.00 to $370.00 and gave the stock a “buy” rating in a report on Friday, October 3rd. Wolfe Research raised their target price on shares of Insulet from $350.00 to $375.00 and gave the company an “outperform” rating in a research note on Friday. Finally, Barclays boosted their price target on shares of Insulet from $300.00 to $301.00 and gave the stock an “equal weight” rating in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, Insulet presently has a consensus rating of “Moderate Buy” and a consensus price target of $370.76.

Insulet Price Performance

Shares of PODD opened at $319.82 on Friday. The stock has a market cap of $22.51 billion, a P/E ratio of 97.21, a price-to-earnings-growth ratio of 2.64 and a beta of 1.39. Insulet Corporation has a 1 year low of $230.05 and a 1 year high of $353.50. The stock’s 50-day moving average price is $325.06 and its two-hundred day moving average price is $309.86. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 EPS for the quarter, beating analysts’ consensus estimates of $1.13 by $0.11. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The company had revenue of $521.70 million during the quarter, compared to analysts’ expectations of $678.70 million. During the same period in the prior year, the business posted $1.08 EPS. Insulet’s revenue was up 29.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, equities analysts predict that Insulet Corporation will post 3.92 earnings per share for the current year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.